Skip to main content

Table 1 Clinical data of the studied groups

From: Epigenetic effects toward new insights as potential therapeutic target in B-thalassemia

Groups Patients (n = 40) Controls (n = 20) P value
Variables
Sex
Male (n-%) 20–50% 14–70% 0.26
Female (n-%) 20–50% 6–30%  
Age (years)
Range 0.5–16 6–12 0.06
Mean ± SD 5.16 ± 4.7 8.4 ± 2.12
Age of onset (month)
Range 3-36  
Mean ± SD 12.87 ± 10.7   
Interval of transfusion (weeks)
Range 3–8  
Mean ± SD 5.1 ± 2.02   
Hemoglobin (g/dL)
Mean ± SD 7.2 ± 1.3 12.18 ± 1.0 < 0.0001***
Hematocrit (%)
Mean ± SD 21.4 ± 4.0 38.9 ± 2.6 < 0.0001***
RBCs count (×106/μL)
Mean ± SD 3.0 ± 0.44 4.66 ± 0.49 < 0.0001***
MCV (fL)
Mean ± SD 65.6 ± 12.5 87.29 ± 5.23 < 0.0001***
MCH (pg)
Mean ± SD 20.8 ± 5.2 29.2 ± 2.37 < 0.0001***
RDW (%)
Mean ± SD 28.0 ± 8.3 13.3 ± 1.58 0.002**
PLT (×106/μL)
Mean ± SD 426 ± 36.8 308 ± 54 0.004**
TLC (×103/μL)
Mean ± SD 16.1 ± 1.9 6.1 ± 1.7 0.001**
Reticulocytes count (%)
Mean ± SD 4.8 ± 1.28 1.4 ± 0.39 0.02*
Serum Ferritin (ng/ml)
Mean ± SD 1161.8 ± 245 143.4 ± 24.49 0.003**
Hemoglobin electrophoresis
HbA (%): Mean ± SD 42.5 ± 30.6 97.55 ± 0.5 < 0.0001***
HbF (%): Mean ± SD 53.5 ± 33.5 0.58 ± 0.18 < 0.0001***
HbA2 (%): Mean ± SD 2.8 ± 1.4 1.76 ± 0.56 0.001**